A case of complete response to avelumab plus axitinib combination therapy for metastatic clear cell renal cell carcinoma in a kidney undergoing dialysis
© 2024 The Authors. IJU Case Reports published by John Wiley & Sons Australia, Ltd on behalf of Japanese Urological Association..
Introduction: Combination therapies of immune checkpoint and tyrosine kinase inhibitors for end-stage kidney disease and patients on hemodialysis need careful consideration as few case reports provide suitable management decisions.
Case presentation: A 70-year-old man who had undergone hemodialysis for 6 years due to nephrosclerosis. Avelumab plus axitinib combination therapy was performed for repeated lung metastasis, and a complete response was achieved without major side effects.
Conclusion: A complete response was achieved after Ave plus Axi combination therapy for clear cell renal cell carcinoma in a patient undergoing dialysis. This suggests that Ave plus Axi combination therapy may be safe and effective for dialysis patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:7 |
|---|---|
| Enthalten in: |
IJU case reports - 7(2024), 2 vom: 28. März, Seite 148-151 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Shiomi, Ei [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Avelumab |
|---|
| Anmerkungen: |
Date Revised 06.03.2024 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1002/iju5.12689 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369305574 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369305574 | ||
| 003 | DE-627 | ||
| 005 | 20240306233340.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240305s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/iju5.12689 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1318.xml |
| 035 | |a (DE-627)NLM369305574 | ||
| 035 | |a (NLM)38440696 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Shiomi, Ei |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A case of complete response to avelumab plus axitinib combination therapy for metastatic clear cell renal cell carcinoma in a kidney undergoing dialysis |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 06.03.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2024 The Authors. IJU Case Reports published by John Wiley & Sons Australia, Ltd on behalf of Japanese Urological Association. | ||
| 520 | |a Introduction: Combination therapies of immune checkpoint and tyrosine kinase inhibitors for end-stage kidney disease and patients on hemodialysis need careful consideration as few case reports provide suitable management decisions | ||
| 520 | |a Case presentation: A 70-year-old man who had undergone hemodialysis for 6 years due to nephrosclerosis. Avelumab plus axitinib combination therapy was performed for repeated lung metastasis, and a complete response was achieved without major side effects | ||
| 520 | |a Conclusion: A complete response was achieved after Ave plus Axi combination therapy for clear cell renal cell carcinoma in a patient undergoing dialysis. This suggests that Ave plus Axi combination therapy may be safe and effective for dialysis patients | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a avelumab | |
| 650 | 4 | |a axitinib | |
| 650 | 4 | |a carcinoma | |
| 650 | 4 | |a immune checkpoint inhibitors | |
| 650 | 4 | |a renal cell | |
| 650 | 4 | |a renal dialysis | |
| 700 | 1 | |a Goto, Yuta |e verfasserin |4 aut | |
| 700 | 1 | |a Hisano, Mizuki |e verfasserin |4 aut | |
| 700 | 1 | |a Ito, Rento |e verfasserin |4 aut | |
| 700 | 1 | |a Moriwaka, Makoto |e verfasserin |4 aut | |
| 700 | 1 | |a Ikarashi, Daiki |e verfasserin |4 aut | |
| 700 | 1 | |a Maekawa, Shigekatsu |e verfasserin |4 aut | |
| 700 | 1 | |a Kato, Renpei |e verfasserin |4 aut | |
| 700 | 1 | |a Kanehira, Mitsugu |e verfasserin |4 aut | |
| 700 | 1 | |a Ujiie, Takashi |e verfasserin |4 aut | |
| 700 | 1 | |a Obara, Wataru |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t IJU case reports |d 2018 |g 7(2024), 2 vom: 28. März, Seite 148-151 |w (DE-627)NLM313187118 |x 2577-171X |7 nnns |
| 773 | 1 | 8 | |g volume:7 |g year:2024 |g number:2 |g day:28 |g month:03 |g pages:148-151 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/iju5.12689 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 7 |j 2024 |e 2 |b 28 |c 03 |h 148-151 | ||